Modified Photochemical Properties of Mitoxantrone by Plasmonic Photothermal Response of Hollow Gold Nanoshells

Document Type : Original Paper


1 mashhad university of medical science,medical physics department

2 Master student of medical biochemistry, Shiraz university of medical sciences

3 Medical Physics Dept., Mashhad University of Medical Sciences


Introduction: Mitoxantrone (MX) has been introduced as a photosensitizer drug. However, due to some side effects, the widespread use of this drug has been confronted with some limitations. Hollow gold nanoshells (HGN) have attracted considerable attention due to their interesting photochemical features that can use as nanocarrier. In this paper, the thermal response of MX and the use of this property for thermal effects during the photodynamic process by MX-conjugated HGN were investigated.
Material and Methods: After optimizing the synthesis of ultimate nanostructure, the characteristics of pharmacological agents including MX, HGN, methoxy polyethylene glycol (mPEG)-HGN, and MX-mPEG-HGN were determined. Then, the thermal response of MX was determined at 0-50°C. Finally, by applying light irradiation with a non-coherent source at a wavelength of 670 nm and exposures of 0 to 50 j/cm2, the profile release and temperature variation in MX-mPEG-HGN were determined.
Results: The zeta potentials of HGN and MX were negative, which resulted in electrostatic repulsion between them. In order to solve this challenge, the surface modification of HGN with mPEG was performed, resulting in the chemical bonding of the drug with the nanostructures and increasing the stability of the final nanostructure. With increasing temperature, the optical density of the drug at 660 nm significantly increased, which is an effective induction of photodynamic effect.
Conclusion: In this study, we used mPEG-HGN as the nanocarrier for MX. Also, the thermal behavior of MX was recognized as an important factor in increasing temperature that could improve the photodynamic process.


Main Subjects

  1. References


    1. Allison RR, Mota HC, Sibata CH. Clinical PD/PDT in North America: An historical review. Photodiagnosis Photodyn Ther. 2004;1(4):263-77.
    2. Castano AP, Demidova TN, Hamblin MR. Mechanisms in photodynamic therapy: part one—photosensitizers, photochemistry and cellular localization. Photodiagnosis and Photodynamic Therapy. 2004;1(4):279-93.
    3. Robertson CA, Evans DH, Abrahamse H. Photodynamic therapy (PDT): a short review on cellular mechanisms and cancer research applications for PDT. Journal of photochemistry and photobiology B, Biology. 2009;96(1):1-8.
    4. Khdair A, Chen D, Patil Y, Ma L, Dou QP, Shekhar MPV, et al. Nanoparticle-mediated combination chemotherapy and photodynamic therapy overcomes tumor drug resistance. Journal of controlled release : official journal of the Controlled Release Society. 2010;141(2):137-44.
    5. Wrzesien-Kus A, Robak T, Jamroziak K, Wierzbowska A, Dmoszynska A, Adamczyk-Cioch M, et al. The treatment of acute myeloid leukemia with mitoxantrone, etoposide and low-dose cytarabine in elderly patients - a report of Polish Acute Leukemia Group (PALG) phase II study. Neoplasma. 2002;49(6):405-11.
    6. Shpall EJ, Jones RB, Holland JF, Bhardwaj S, Paciucci PA, Wilfinger CL, et al. Intensive single-agent mitoxantrone for metastatic breast cancer. Journal of the National Cancer Institute. 1988;80(3):204-8.
    7. Armitage JO. The role of mitoxantrone in non-Hodgkin's lymphoma. Oncology (Williston Park, NY). 2002;16(4):490-502.
    8. Montazerabadi A-R, Sazgarnia A, Bahreyni-Toosi MH, Ahmadi A, Shakeri-Zadeh A, Aledavood A. Mitoxantrone as a prospective photosensitizer for photodynamic therapy of breast cancer. Photodiagnosis and Photodynamic Therapy. 2012;9(1):46-51.
    9. Feofanov A, Sharonov S, Kudelina I, Fleury F, Nabiev I. Localization and molecular interactions of mitoxantrone within living K562 cells as probed by confocal spectral imaging analysis. Biophysical journal. 1997;73(6):3317-27.
    10. Foye WO, Vajragupta O, Sengupta SK. DNA‐binding specificity and RNA polymerase inhibitory activity of bis (aminoalkyl) anthraquinones and bis (methylthio) vinylquinolinium iodides. Journal of pharmaceutical sciences. 1982;71(2):253-7.
    11. Bradbury EM, Van Holde K. Chromatin structure and dynamics: a historical perspective. New Comprehensive Biochemistry. 2004;39:1-11.
    12. He S, Dunn KL, Espino PS, Drobic B, Li L, Yu J, et al. Chromatin organization and nuclear microenvironments in cancer cells. Journal of cellular biochemistry. 2008;104(6):2004-15.
    13. Hajihassan Z, Rabbani-Chadegani A. Studies on the binding affinity of anticancer drug mitoxantrone to chromatin, DNA and histone proteins. Journal of biomedical science. 2009;16(1):31.
    14. Homolya L, Orbán TI, Csanády L, Sarkadi B. Mitoxantrone is expelled by the ABCG2 multidrug transporter directly from the plasma membrane. Biochimica et Biophysica Acta (BBA) - Biomembranes. 2011;1808(1):154-63.
    15. Ho CK, Law SL, Chiang H, Hsu ML, Wang CC, Wang SY. Inhibition of microtubule assembly is a possible mechanism of action of mitoxantrone. Biochem Biophys Res Commun. 1991;180(1):118-23.
    16. Ho C-K, Law S-L, Chiang H, Hsu M-L, Wang C-C, Wang S-Y. Inhibition of microtubule assembly is a possible mechanism of action of mitoxantrone. Biochemical and biophysical research communications. 1991;180(1):118-23.
    17. Chavan S, Parekh H, Chitnis M. Antineoplastic activity of mitoxantrone and its biological interactions in parental and multidrug resistant subline of P388 murine leukemia cells. Neoplasma. 1992;39(1):49-57.
    18. Safa AR, Chegini N, Tseng MT. Influence of mitoxantrone on nucleic acid synthesis on the T-47D breast tumor cell line. J Cell Biochem. 1983;22(2):111-20.
    19. Kapuscinski J, Darzynkiewicz Z, Traganos F, Melamed MR. Interactions of a new antitumor agent, 1, 4-dihydroxy-5, 8-bis [[2-[(2-hydroxyethyl) amino]-ethyl] amino]-9, 10-anthracenedione, with nucleic acids. Biochemical pharmacology. 1981;30(3):231-40.
    20. Fanciullino R, Ciccolini J, Milano G. Challenges, expectations and limits for nanoparticles-based therapeutics in cancer: a focus on nano-albumin-bound drugs. Critical reviews in oncology/hematology. 2013;88(3):504-13.
    21. Brown KR, Walter DG, Natan MJ. Seeding of colloidal Au nanoparticle solutions. 2. Improved control of particle size and shape. Chemistry of Materials. 2000;12(2):306-13.
    22. Imanparast A, Attaran N, Sazgarnia A. In Vitro Investigation into Plasmonic Photothermal Effect of Hollow Gold Nanoshell Irradiated with Incoherent Light. Iranian Journal of Medical Physics. 2018;15(3):161-8.
    23. Ren Q-Q, Bai L-Y, Zhang X-S, Ma Z-Y, Liu B, Zhao Y-D, et al. Preparation, Modification, and Application of Hollow Gold Nanospheres. Journal of Nanomaterials. 2015;2015:7.
    24. Melancon MP, Lu W, Yang Z, Zhang R, Cheng Z, Elliot AM, et al. In vitro and in vivo targeting of hollow gold nanoshells directed at epidermal growth factor receptors for photothermal ablation therapy. Molecular cancer therapeutics. 2008;7(6):1730-9.
    25. Butcher NJ, Mortimer GM, Minchin RF. Unravelling the stealth effect. Nature Nanotechnology. 2016;11:310.
    26. Cheng Y, Samia AC, Li J, Kenney ME, Resnick A, Burda C. Delivery and efficacy of a cancer drug as a function of the bond to the gold nanoparticle surface. Langmuir. 2009;26(4):2248-55.
    27. Coates J. Interpretation of infrared spectra, a practical approach. Encyclopedia of analytical chemistry. 2000;12:10815-37.
    28. Toh T-B, Lee D-K, Hou W, Abdullah LN, Nguyen J, Ho D, et al. Nanodiamond–Mitoxantrone Complexes Enhance Drug Retention in Chemoresistant Breast Cancer Cells. Molecular Pharmaceutics. 2014;11(8):2683-91.
    29. Barar J, Kafil V, Majd MH, Barzegari A, Khani S, Johari-Ahar M, et al. Erratum to: Multifunctional mitoxantrone-conjugated magnetic nanosystem for targeted therapy of folate receptor-overexpressing malignant cells. Journal of Nanobiotechnology. 2015;13(1):59.
    30. Huang X, El-Sayed MA. Plasmonic photo-thermal therapy (PPTT). Alexandria Journal of Medicine. 2011;47(1):1-9.